公开(公告)号：US11976084B2

公开(公告)日：2024-05-07

申请号：US17531844

申请日：2021-11-22

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jun Ma ,  Yong He ,  Xuechao Xing ,  Hui Cao ,  Xuri Gao ,  Xiaowen Peng ,  Joseph D. Panarese ,  Yat Sun Or

IPC: C07D519/00

CPC classification number: C07D519/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220402926A1

公开(公告)日：2022-12-22

申请号：US17719920

申请日：2022-04-13

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jiajun Zhang ,  Xiaowen Peng ,  Byung-Chul Suh ,  Jorden Kass ,  Xuri Gao ,  Hui Cao ,  Wei Li ,  Joseph D. Panarese ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20220162216A1

公开(公告)日：2022-05-26

申请号：US17479244

申请日：2021-09-20

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Yong He ,  Xuri Gao ,  Jun Ma ,  Xuechao Xing ,  Hui Cao ,  Joseph D. Panarese ,  Yat Sun Or

IPC: C07D487/10

Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11034684B2

公开(公告)日：2021-06-15

申请号：US16569819

申请日：2019-09-13

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jun Ma ,  Guoqiang Wang ,  Bin Wang ,  Xuechao Xing ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D417/14 ,  C07D413/14 ,  C07D261/08 ,  C07D413/12

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US11008304B2

公开(公告)日：2021-05-18

申请号：US16400529

申请日：2019-05-01

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Brett Granger ,  Jing He ,  Xuechao Xing ,  Yong He ,  Jiang Long ,  Jun Ma ,  Bin Wang ,  Yat Sun Or

IPC: C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which is associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).

公开(公告)号：US10683289B2

公开(公告)日：2020-06-16

申请号：US16400498

申请日：2019-05-01

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D417/14 ,  A61K31/4164 ,  A61K31/4196 ,  A61K31/4439

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis disease (NASH).

公开(公告)号：US10676500B2

公开(公告)日：2020-06-09

申请号：US15948370

申请日：2018-04-09

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yong He ,  Brett Granger ,  Xuechao Xing ,  Yat Sun Or

IPC: C07J41/00 ,  C07J43/00 ,  C07J51/00 ,  C07J9/00

Abstract: The present invention relates to processes for preparing compounds of Formula (I) and compounds of Formula (II): These compounds are useful as FXR or TGR5 modulators. The present invention also relates to processes for the preparation of the compounds of Formula (III), Formula (IV), Formula (V), and Formula (VI), The present invention also relates to a process for the preparation of compounds (VII), (VIII) and (IX),

公开(公告)号：US20200157095A1

公开(公告)日：2020-05-21

申请号：US16688429

申请日：2019-11-19

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Brett Granger ,  Guoqiang Wang ,  Ruichao Shen ,  Jing He ,  Yong He ,  Xuechao Xing ,  Jun Ma ,  Jiang Long ,  Bin Wang ,  Yat Sun Or

IPC: C07D471/04 ,  C07D401/14 ,  C07D413/14 ,  C07D405/14 ,  C07D417/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts and esters thereof: which inhibit the Apoptosis signal-regulating kinase 1 (ASK-1), which associated with autoimmune disorders, neurodegenerative disorders, inflammatory diseases, chronic kidney disease, cardiovascular disease. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from ASK-1 related disease. The invention also relates to methods of treating an ASK-1 related disease in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention specifically relates to methods of treating ASK-1 associated with hepatic steatosis, including non-alcoholic fatty liver disease (NAFLD) and non-alcohol steatohepatitis disease (NASH).

公开(公告)号：US20200079764A1

公开(公告)日：2020-03-12

申请号：US16569819

申请日：2019-09-13

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jun Ma ,  Guoqiang Wang ,  Bin Wang ,  Xuechao Xing ,  Ruichao Shen ,  Jing He ,  Yat Sun Or

IPC: C07D413/14 ,  C07D413/12 ,  C07D261/08 ,  C07D417/14

Abstract: The present invention provides compounds of Formula I, pharmaceutical compositions comprising these compounds and methods of using these compounds to prevent or treat FXR-mediated or TGR5-mediated diseases or conditions.

公开(公告)号：US10584145B2

公开(公告)日：2020-03-10

申请号：US15826233

申请日：2017-11-29

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Yong He ,  Peng Dai ,  Guoyou Xu ,  Bin Wang ,  Jiang Long ,  Yat Sun Or

IPC: C07J41/00 ,  C07J51/00 ,  C07J9/00

Abstract: The present invention relates to processes for preparing a compound of Formula I: or a pharmaceutically acceptable salt or solvate thereof. These compounds and pharmaceutical compositions are useful as FXR or TGR5 modulators. Specifically, the present invention relates to bile acid derivatives and methods for their preparation and use. The present invention relates to a process for the preparation of a compound (II) and its salts and derivatives which are useful intermediates in the synthesis of biologically active molecules, especially in the synthesis of FXR and TGR5 modulators. The present invention also relates to a process for the preparation of a compound (III) and its diethylamine salt.